Trial · NCT06176911
The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
NCT06176911, Phase 2, Unknown, Peking University People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia. Trials, record NCT06176911. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06176911
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
- NCT number
- NCT06176911
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 124 participants, estimated
- Lead sponsor
- Peking University People's Hospital
- Conditions
- Immune Thrombocytopenia
- Interventions
- Teriflunomide, Danazol
- First posted
- 2023-12-20
- Last updated
- 2023-12-20
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sustained response | From the start of study treatment (Day 1) to the end of week 24 | Platelet count over 30,000/μL and at least a 2-fold increase of the baseline count in the absence of bleeding and rescue therapy for at least four of the six visits between weeks 19 and 24. |
| Secondary | Overall response | From the start of study treatment (Day 1) to the end of week 24 | Complete response (CR) was defined as platelet count over 100,000/μL and absence of bleeding. Response (R) was defined as platelet count over 30,000/μL and at least a 2-fold increase of the baseline count and absence of bleeding. |
| Secondary | Time to response | From the start of study treatment (Day 1) to the end of week 24 | The time from treatment initiation to achieve a CR or a R. |
| Secondary | Duration of response | From the start of study treatment (Day 1) to the end of week 24 | The time from the achievement of a complete response or a partial response to the loss of response. |
| Secondary | Initial response | From the start of study treatment (Day 1) up to week 4 of treatment | The number of participants with achievement of CR or R at 4 weeks. |
| Secondary | Bleeding events | From the start of study treatment (Day 1) to the end of week 24 | Clinically significant bleeding was assessed using the World Health Organization (WHO) bleeding scale. |
| Secondary | Adverse events | From the start of study treatment (Day 1) to the end of week 24 | Adverse events (AEs) were reported and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. |
| Secondary | Health-related quality of life (HRQoL) | From the start of study treatment (Day 1) to the end of week 24 | ITP-PAQ was used to assess the Health-Related Quality of Life (HRQoL) before and after treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06176911
GET https://conductscience.org/api/trials/v1/NCT06176911/registered